Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886576 | 0.90 | CYP11B1 (0.43) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL24004291 | 0.83 | SMN1; SMN2 (0.39) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL10200639 | 0.80 | CYP11B1 (0.45) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL25051581 | 0.79 | TSHR (0.41) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL17166457 | 0.79 | TSHR (0.41) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL25051602 | 0.79 | TSHR (0.41) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL24938398 | 0.75 | CD274 (0.45) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL22047418 | 0.75 | CYP11B1 (0.39) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL22047376 | 0.75 | CYP11B1 (0.39) | CYP11B1CYP11B2PDCD1LG2CD274OPRM1 | |
| SCHEMBL16627076 | 0.74 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | CYP11B1 3552/4885CYP11B2 3847/4885PDCD1LG2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.